big there are so many tumour types that vis could be used for. decisions to initiate trials for other cancers would involve considering the tons of competition who have many different targets and the length of time to get from ind to approval. gen/roche have already looked a some of the other possible indications and started a few new trials in the last 6 months. it will be interesting to see if they add any more. i have disagreed with people on this board who say there is no downside for this company/stock, but long-term i think this is a great hold even amid this tremendous volatility. it has also been great for short term trading. i expect decent results, and subsequent approval, from the phiii gem/abraxane pancreatic trial, the results of which will probably be reported in september, in my opinion. so, as i have stated so many times, the first test (after vis for bbc) is for the triple gem/abraxane/vis for pancreatic, which i hope will be presented at the su2c show and show better results than the gem/abraxane alone - keeping in mind that our trial is a phii.
I hope you are correct about Sept results for the triple pancreatic trial. My little nagging fear is that they will need to modify the dosing to be like the gem/0449 study where 0449 was given first then gem was given to get better results. I sure hope we get good news of that or lung soon. If we receive positive news at the SU2C TV event next month that would be huge. GLTA and here's to hoping the drip, drip, drip has dried up.